A5055201057- Health Systems, Economic Evaluations, Quality of Life
- Lipoproteins and Cardiovascular Health
- Pharmaceutical Economics and Policy
- Epilepsy research and treatment
- Pharmaceutical Practices and Patient Outcomes
- Global Public Health Policies and Epidemiology
- Acute Ischemic Stroke Management
- Diabetes Treatment and Management
- Pharmacological Effects and Toxicity Studies
- Diabetes, Cardiovascular Risks, and Lipoproteins
- Stroke Rehabilitation and Recovery
- Biochemical effects in animals
- Health and Medical Research Impacts
- Vitamin D Research Studies
- Medication Adherence and Compliance
- Diabetes Management and Research
- Cardiovascular Health and Risk Factors
- Healthcare cost, quality, practices
- Hip and Femur Fractures
- Cardiac Health and Mental Health
- Bone health and osteoporosis research
- Genomics, phytochemicals, and oxidative stress
- Gestational Diabetes Research and Management
- Stress Responses and Cortisol
- Metabolism, Diabetes, and Cancer
Monash University
2018-2025
Australian Regenerative Medicine Institute
2023-2024
The Royal Melbourne Hospital
2023
Florey Institute of Neuroscience and Mental Health
2023
Austin Hospital
2023
Alfred Health
2023
The University of Melbourne
2022-2023
Monash Institute of Medical Research
2023
Westmead Institute
2023
Westmead Hospital
2023
To estimate the health and economic burden of new established cardiovascular disease from 2020 to 2029 in Australia.A two-stage multistate dynamic model was developed predict incident prevalent disease, for Australians 40-90 years old 2029. The captured morbidity, mortality, life lived, quality-adjusted years, healthcare costs, productivity losses. Cardiovascular risk primary prevention population derived using Australian demographic data Pooled Cohort Equation. Risk secondary REACH...
The aim of this study was to assess the impact and cost-effectiveness offering population genomic screening all young adults in Australia detect heterozygous familial hypercholesterolaemia (FH).We designed a decision analytic Markov model compare current standard care for FH diagnosis (opportunistic cholesterol genetic cascade testing) with alternate strategy aged 18-40 years pathogenic variants LDLR/APOB/PCSK9 genes. We used validated cost-adaptation method adapt findings eight high-income...
Abstract Aims/hypothesis Whether sodium–glucose co-transporter 2 inhibitors (SGLT2is) or glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are cost-effective based solely on their cardiovascular and kidney benefits is unknown. We projected the health economic outcomes due to myocardial infarction (MI), stroke, heart failure (HF) end-stage disease (ESKD) among people with type diabetes, without CVD, under scenarios of widespread use these drugs. Methods designed a microsimulation model...
The aim was to project the health and economic outcomes of cardiovascular disease (CVD) among people with type 2 diabetes from Australian public healthcare societal perspectives over next decade. A dynamic multistate model yearly cycles developed events Australians aged 40–89 years 2022 2031. CVD risk (myocardial infarction [MI] stroke) in population estimated using 2013 pooled cohort equation, recurrent event rates established were obtained global Reduction Atherothrombosis for Continued...
Abstract Aims/hypothesis The aim of this study was to determine the long-term cost-effectiveness and return on investment implementing a structured lifestyle intervention reduce excessive gestational weight gain associated incidence diabetes mellitus (GDM) type 2 mellitus. Methods A decision-analytic Markov model used compare health outcomes for (1) during pregnancy prevent GDM subsequent diabetes; (2) current usual antenatal care. Life table modelling capture morbidity, mortality...
We aimed to assess the cost effectiveness of four different lipid-lowering strategies for primary prevention coronary heart disease initiated at ages 30, 40, 50, and 60 years from UK National Health Service perspective. developed a microsimulation model comparing initiation strategy current standard care (control). included 458,692 participants Biobank study. The were: (1) low/moderate-intensity statins; (2) high-intensity (3) statins ezetimibe; (4) inclisiran. main outcome was incremental...
Abstract Objective Epilepsy is a common and serious neurological disorder. This cross‐sectional analysis addresses the burden of epilepsy at different stages disease. Methods pilot study embedded within Australian Project (AEP), aiming to provide support through national network dedicated sites. For this analysis, adults aged 18–65 years with first unprovoked seizure (FUS), newly diagnosed (NDE), or drug‐resistant (DRE) were recruited between February–August 2022. Baseline clinicodemographic...
Abstract Objective The aim of this study was to compare the risk seizure, recurrent stroke, fall or fracture, and mortality in individuals prescribed different antiseizure medications (ASMs) following an ischemic stroke. Methods We identified all patients admitted a Victorian public private hospital with principal diagnosis incident stroke between 2013 2017 dispensed ASM within 12 months discharge. Cox proportional hazards regression used estimate cause‐specific rehospitalization emergency...
Current clinical guidelines recommend a drug holiday after extended use of oral bisphosphonates. However, no studies have investigated the effect holidays before hip fractures on postfracture mortality.
Hip fractures are a major public health concern. Number of hip cases increased by 20% from 2012 to 2018. Factors associated with post-fracture mortality included men, those who frail, living in non-metropolitan region, or residing residential aged care facility. Our results useful for planning healthcare interventions.
Lower copy number variations (CNVs) in the salivary amylase gene (AMY1) have been associated with obesity and insulin resistance; however, relationship between AMY1 cardiometabolic risk has not fully elucidated. Using gold-standard measures, we aimed to examine whether CNVs are factors an overweight or obese, otherwise healthy population. Fifty-seven adults (58% male) aged 31.17 ± 8.44 years a body mass index (BMI) ≥25 kg/m² were included study. We measured (qPCR); anthropometry (BMI;...
No previous health-economic evaluation has assessed the impact and cost-effectiveness of offering combined adult population genomic screening for mutliple high-risk conditions in a national public healthcare system.
To evaluate the population health returns from investment in Victorian Cancer Biobank (VCB), a research consortium including five hospital-integrated sample repositories located Melbourne, Australia.